Deborah Pat Staton, MA,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Rr 1 Box 172, Versailles, IL 62378 Phone: 217-225-3531 Fax: 217-225-3181 |
News Archive
Saint Louis University researchers believe they've won a major skirmish in the battle of the bulge, and their findings are published in the May issue of Diabetes.
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.
Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.
Colorectal cancer is the second most common cause of cancer-related mortality among men and women in the United States, according to the American Cancer Society. At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening.
Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.
› Verified 6 days ago